194 related articles for article (PubMed ID: 36063959)
1. A single-beam of light priming the immune responses and boosting cancer photoimmunotherapy.
Sun Y; Han R; Wang J; Qin Y; Ren Z; Feng X; Liu Q; Wang X
J Control Release; 2022 Oct; 350():734-747. PubMed ID: 36063959
[TBL] [Abstract][Full Text] [Related]
2. Size-optimized nuclear-targeting phototherapy enhances the type I interferon response for "cold" tumor immunotherapy.
Zhang X; Yi C; Zhang L; Zhu X; He Y; Lu H; Li Y; Tang Y; Zhao W; Chen G; Wang C; Huang S; Ouyang G; Yu D
Acta Biomater; 2023 Mar; 159():338-352. PubMed ID: 36669551
[TBL] [Abstract][Full Text] [Related]
3. Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy.
Lu Q; Qi S; Li P; Yang L; Yang S; Wang Y; Cheng Y; Song Y; Wang S; Tan F; Li N
J Mater Chem B; 2019 Apr; 7(15):2499-2511. PubMed ID: 32255127
[TBL] [Abstract][Full Text] [Related]
4. Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity.
Taki S; Matsuoka K; Nishinaga Y; Takahashi K; Yasui H; Koike C; Shimizu M; Sato M; Sato K
J Immunother Cancer; 2021 Oct; 9(11):. PubMed ID: 34725216
[TBL] [Abstract][Full Text] [Related]
5. Photothermal-Activatable Fe
Ge R; Liu C; Zhang X; Wang W; Li B; Liu J; Liu Y; Sun H; Zhang D; Hou Y; Zhang H; Yang B
ACS Appl Mater Interfaces; 2018 Jun; 10(24):20342-20355. PubMed ID: 29878757
[TBL] [Abstract][Full Text] [Related]
6. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
7. Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer.
Zhao Y; Liu X; Liu X; Yu J; Bai X; Wu X; Guo X; Liu Z; Liu X
Front Immunol; 2022; 13():955920. PubMed ID: 36119019
[TBL] [Abstract][Full Text] [Related]
8. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
[TBL] [Abstract][Full Text] [Related]
9. Multimodal Imaging-Guided Photoimmunotherapy of Pancreatic Cancer by Organosilica Nanomedicine.
Zhang H; Chen K; Guo K; Tao J; Song L; Ren S; Zhao Y; Teng Z; Qiu W; Wang Z
Adv Healthc Mater; 2024 Jan; 13(2):e2302195. PubMed ID: 37792547
[TBL] [Abstract][Full Text] [Related]
10. Allomelanin-based biomimetic nanotherapeutics for orthotopic glioblastoma targeted photothermal immunotherapy.
Sun M; Li Y; Zhang W; Gu X; Wen R; Zhang K; Mao J; Huang C; Zhang X; Nie M; Zhang Z; Qi C; Cai K; Liu G
Acta Biomater; 2023 Aug; 166():552-566. PubMed ID: 37236575
[TBL] [Abstract][Full Text] [Related]
11. Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade.
Appleton E; Hassan J; Chan Wah Hak C; Sivamanoharan N; Wilkins A; Samson A; Ono M; Harrington KJ; Melcher A; Wennerberg E
Front Immunol; 2021; 12():754436. PubMed ID: 34733287
[TBL] [Abstract][Full Text] [Related]
12. Near-Infrared II Nanoadjuvant-Mediated Chemodynamic, Photodynamic, and Photothermal Therapy Combines Immunogenic Cell Death with PD-L1 Blockade to Enhance Antitumor Immunity.
Xiang Q; Yang C; Luo Y; Liu F; Zheng J; Liu W; Ran H; Sun Y; Ren J; Wang Z
Small; 2022 Apr; 18(13):e2107809. PubMed ID: 35143709
[TBL] [Abstract][Full Text] [Related]
13. Reprogramming the Tumor Microenvironment through Second-Near-Infrared-Window Photothermal Genome Editing of PD-L1 Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy.
Tang H; Xu X; Chen Y; Xin H; Wan T; Li B; Pan H; Li D; Ping Y
Adv Mater; 2021 Mar; 33(12):e2006003. PubMed ID: 33538047
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
15. Mace-Like Plasmonic Au-Pd Heterostructures Boost Near-Infrared Photoimmunotherapy.
Feng Y; Ning X; Wang J; Wen Z; Cao F; You Q; Zou J; Zhou X; Sun T; Cao J; Chen X
Adv Sci (Weinh); 2023 Feb; 10(6):e2204842. PubMed ID: 36599677
[TBL] [Abstract][Full Text] [Related]
16. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
McAuliffe J; Chan HF; Noblecourt L; Ramirez-Valdez RA; Pereira-Almeida V; Zhou Y; Pollock E; Cappuccini F; Redchenko I; Hill AV; Leung CSK; Van den Eynde BJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479921
[TBL] [Abstract][Full Text] [Related]
17. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
18. A review of immune checkpoint blockade in breast cancer.
Pellegrino B; Tommasi C; Cursio OE; Musolino A; Migliori E; De Silva P; Senevirathne TH; Schena M; Scartozzi M; Farci D; Willard-Gallo K; Solinas C
Semin Oncol; 2021 Jun; 48(3):208-225. PubMed ID: 34620502
[TBL] [Abstract][Full Text] [Related]
19. Nanocodelivery of an NIR photothermal agent and an acid-responsive TLR7 agonist prodrug to enhance cancer photothermal immunotherapy and the abscopal effect.
Chen B; Huang R; Zeng W; Wang W; Min Y
Biomaterials; 2024 Mar; 305():122434. PubMed ID: 38141501
[TBL] [Abstract][Full Text] [Related]
20. Targeted NIR-responsive theranostic immuno-nanomedicine combined TLR7 agonist with immune checkpoint blockade for effective cancer photothermal immunotherapy.
Yasothamani V; Vivek R
J Mater Chem B; 2022 Aug; 10(33):6392-6403. PubMed ID: 35971846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
